Publications by authors named "B Bermejo"
Gestational breast cancer: distinctive molecular and clinico-epidemiological features.
J Mammary Gland Biol Neoplasia
November 2024
Gestational breast cancer (GBC), defined as breast cancer (BC) diagnosed during pregnancy or the first-year post-partum, accounts for 6-15% of BC cases in women aged 20-44 years. GBC has worse prognosis than non-GBC, but reasons behind are not clear. The GEICAM/2012-03 Study (Molecular Characterization of Gestational Breast Cancer) is a multicenter prospective/retrospective observational registry of patients diagnosed with GBC.
View Article and Find Full Text PDFBackground: The effect of the addition of cyclin-dependent kinases 4 and 6 inhibitors to endocrine therapy in terms of molecular downstaging remains undetermined. Switching from a high-risk to a low risk Recurrence Score (RS) group could provide useful information to identify patients who might not require chemotherapy. The purpose of this study was to assess the biological and clinical activity of letrozole plus palbociclib as neoadjuvant treatment for patients with hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer with an initial Oncotype DX RS ≥18.
View Article and Find Full Text PDFPurpose: We assessed the 27-gene RT-qPCR-based DetermaIO assay and the same score calculated from RNA sequencing (RNA-seq) data as predictors of sensitivity to immune checkpoint therapy in the neoTRIPaPDL1 randomized trial that compared neoadjuvant carboplatin/nab-paclitaxel chemotherapy (CT) plus atezolizumab with CT alone in stage II/III triple-negative breast cancer. We also assessed the predictive function of the immuno-oncology (IO) score in expression data of patients treated with pembrolizumab plus paclitaxel (N = 29) or CT alone (N = 56) in the I-SPY2 trial.
Experimental Design: RNA-seq data were obtained from pretreatment core biopsies from 242 (93.
Article Synopsis
- This study looked at how a medicine called nintedanib might help with breast cancer by making the environment around the tumor less stiff.
- Researchers tested this by comparing two groups of patients: one got regular treatment while the other received nintedanib with their treatment.
- They found that although overall survival rates were similar, patients with high stiffness scores (MeCo) had a higher risk of cancer returning, but taking nintedanib lowered that risk.
Article Synopsis
- Some breast cancer patients continue to relapse because their cancer becomes resistant to treatment.
- This study focused on a group of tiny molecules called microRNAs, specifically the microRNA-449 family, and how they are involved in making breast cancer more resistant to a drug called doxorubicin.
- The researchers found that levels of these microRNAs are low in a specific type of breast cancer (triple-negative), and they could be helpful for doctors to diagnose and treat this kind of cancer better.